Possible structural and functional determinants contributing to the clastogenicity of pharmaceuticals

Environmental and Molecular Mutagenesis

Volumn 51, Issue 8-9, 2010, Pages 800-814

  Snyder, Ronald D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Intercalation; Non covalent binding; Pharmaceuticals; Topoisomerase

Indexed keywords

ACLARUBICIN; ALMOTRIPTAN; AMFEPRAMONE; AMITRIPTYLINE; AMONAFIDE; APRINDINE; AURAMINE; AZAPROPAZONE; BAMBUTEROL; BROMPHENIRAMINE; CABERGOLINE; CHLOROPYRILENE; CHLOROQUINE; CHLORPHENIRAMINE; CHLORPROMAZINE; CHLORPROTHIXENE; CITALOPRAM; CLOMIFENE; CLOMIPRAMINE; CLORICROMEN; CYAMEMAZINE; DACARBAZINE; DAMINOZIDE; DNA TOPOISOMERASE; FORSKOLIN; KETONE; MUTAGENIC AGENT; PIPERIDINE; PYRIDINE; UNINDEXED DRUG; DRUG; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

AMES TEST; CHROMOSOME ABERRATION; COVALENT BOND; CYTOTOXICITY; DRUG DNA INTERACTION; ENZYME BINDING; GENOTOXICITY; HUMAN; INTERCALATION COMPLEX; MUTAGENESIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG TOXICITY; MUTAGEN TESTING;

MAMMALIA;

DRUG TOXICITY; HUMANS; KETONES; MOLECULAR STRUCTURE; MUTAGENICITY TESTS; MUTAGENS; PHARMACEUTICAL PREPARATIONS; PIPERIDINES; PYRIDINES;

EID: 78349277240     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20626     Document Type: Review

References (50)

1. Bal C, Baldeyrou B, Moz F, Lansiaux A, Colson P, Kraus-Berthier L, Leonce S, Pierre A, Boussard M-F, Rousseau A, Wierzbicki M, Bailly C. 2004. Novel antitumor indenoindole derivatives targeting DNA, topoisomerase II. Biochem Pharmacol 68: 1911-1922.
2. Bandele OJ, Osheroff N. 2008. (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chem Res Toxicol 21: 936-943.
3. Barabus K, Molnar J. 1980. Lack of correlation between intercalation and plasmid curing ability of some tricyclic compounds. Acta Microbiol Acad Sci Hung 27: 55-61.
4. Brambilla G, Martelli A. 2009. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat Res 681: 209-229.
5. Darkin S, McQuillan J, Ralph RK. 1984. Chlorpromazine: A potential anticancer agent? Biochem Biophys Res Commun 30: 184-191.
6. Deweese JE, Osheroff N. 2009. The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing. Nucleic Acids Res 373: 738-748.
7. Ebert BL, Niemerko E, Shaffer K, Salfia R. 2003. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 8: 69-75.
8. Galloway SM, Aardema MJ, Ishidate MJ, Ivett JL, Kirkland DJ, Morita T, Mossesso P, Sofuni T. 1994. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res 312: 241-261.
9. Gomez L, Hack MD, Wu J, Wiener JJM, Venkatesan H, Santillan A, Pippel DJ, Mani N, Morrow BJ, Motley ST, Shaw KJ, Wolin R, Grice CA, Jones TK. 2007. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part I. Synthesis and preliminary SAR analysis. Bioorg Med Chem Lett 17: 2723-2727.
10. Hendry LB, Bransome EDJr, Mahesh VB. 1998. The ligand insertion hypothesis in the genomic action of steroid hormones. J Steroid Biochem Mol Biol 65: 75-89.
11. Hilliard C, Hill R, Armstrong M, Fleckenstein C, Crowley J, Freeland E, Duffy D, Galloway SM. 2007. Chromosome aberrations in Chinese hamster and human cells: A comparison using compounds with various genotoxicity profiles. Mutat Res 616: 103-118.
12. Holt PA, Chaires JB, Trent JO. 2008. Molecular docking of intercalators and groove-binders to nucleic acids using autodock and surflex. J Chem Inf Model 48: 1602-1615.
13. IARC, Caprolactam (Group 4). 1991. Summary of data reported and evaluation. 71: 383
14. ICPEMC (International Commission for Protection Against Environmental Mutagens and carcinogens). 1991. Genotoxicity under extreme culture conditions. Mutat Res 257: 147-204.
15. Kirkland D, Aardema M, Henderson L, Muller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat Res 584: 1-256.
16. Langer SP, Schmidt G, Sorensen M, Sehested M, Jensen PB. 1999. Inhibitors of topoisomerase II as pH-dependent modulators of etoposide-mediated cytotoxicity. Clin Cancer Res 5: 2899-2907.
17. Mahesh VB, Roach LW, Cannady WE, Ogle TF, Brann DW, Bransome EDJr, Hendry LB. 2001. Gene based pharmacophores for drug design. Med Chem Res 10: 440-455.
18. Mitscher LA. 2005. Bacterial topoisomerase inhibitors: Quinolone and pyridine antibacterial agents. Chem Rev 105: 559-592.
19. Mizushima T, Natori S, Sekimizu K. 1992. Inhibition of Escherichia coli DNA topoisomerase I activity by phospholipids. Biochem J 285: 503-506.
20. Nacro K, Zha C, Guzzo PR, Herr RJ, Peace D, Friedrich TD. 2007. Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted lutonin A derivatives. Biorg Med Chem 15: 4237-4246.
21. Nitiss JL. 1998. DNA topoisomerases in DNA repair and DNA damage tolerance. In Nickoloff JKA, Hoekstra MF, editors. DNA Damage and Repair, Vol 2: DNA Repair in Higher Eukaryotes. Totowa, NJ: Humana Press. p. 517-537.
22. Portugal J. 1994. Berenil acts as a poison of eucaryotic topoisomerase II. FEBS Lett 344: 136-138.
23. Rhee H-K, Park HJ, Lee SK, Lee C-O, Choo H-YP. 2007. Synthesis cytotoxicity and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem 15: 1651-1658.
24. Sabourin M, Osheroff N. 2000. Sensitivity of human type II topoisomerases to DNA damage: Stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res 28: 1947-1954.
25. Saravana KR, Moorthy N SHN, Trivedi P. 2003. QSAR studies and molecular shape analysis of azonafide derivatives as topoisomerase II inhibitors. Indian J Pharm Sci 65: 346-350.
26. Sato T, Matsuo Y, Honma T, Yokoyama S. 2008. In silico functional profiling of small molecules and its applications. J Med Chem 51: 7705-7716.
27. Shin CG, Strayer JM, Wani MA, Snapka RM. 1990. Rapid evaluation of topoisomease inhibitors: Caffeine inhibition of topoisomerases in vivo. Teratog Carcinog Mutagen 10: 41-52.
28. Sim S-P, Gatto B, Yu C, Liu AA, Li T-K, Pilch DS, LaVoie EJ, Liu LF. 1997. Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove binding nogalose sugar. Biochemistry 36: 13285-13291.
29. Snyder RD. 1998. A review and investigation into the mechanistic basis for the genotoxicity of antihistamines. Mutat Res 411: 235-248.
30. Snyder RD. 2000. The use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen 35: 13-21.
31. Snyder RD. 2003. Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons. Drug Chem Toxicol 26: 15-22.
32. Snyder RD 2007. Non-covalent chemical/DNA interactions: Mechanisms and consequences. Mutat Res 623: 1-2.
33. Snyder RD. 2009. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environ Mol Mutagen 50: 435-450.
34. Snyder RD, Strekowski L. 1999. Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA-binding compounds. Mutat Res 444: 181-192.
35. Snyder RD, Diehl MS. 2000. The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalative agents. Mutagen 15: 203-205.
36. Snyder RD, Arnone MR. 2002. Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat Res 503: 21-35.
37. Snyder RD, Brown JE. 2002. Evidence for and role of the dimethylamino group in tamoxifen DNA intercalation in intact Chinese hamster V79 cells. Drug Chem Toxicol 25: 473-479.
38. Snyder RD, Gillies PJ. 2002. Evaluation of the clastogenic, DNA intercalative and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ Mol Mutagen 40: 266-276.
39. Snyder RD, Ewing DE, Hendry LB. 2004a. Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell-based and three-dimensional computational approaches. Environ Mol Mutagen 44: 163-173.
40. Snyder RD, Pearl GS, Mandakas G, Choy W-N, Goodsaid F, Rosenblum IY. 2004b. Assessment of the sensitivity of the computational programs DEREK, TOPKAT and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ Mol Mutagen 43: 143-158.
41. Snyder RD, McNulty J, Zairov G, Ewing DE, Hendry LB. 2005. The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mutat Res 578: 88-99.
42. Snyder RD, Ewing D, Hendry LB. 2006. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat Res 609: 47-59.
43. Speit G, Vogel W. 1979. The effect on sister chromatid exchanges of drugs and dyes by intercalation and photoactivation. Mutat Res 59: 223-229.
44. Strekowski L. 1992. Molecular basis for the enhancement or inhibition of bleomycin-mediated degradation of DNA by DNA binding compounds. Adv Detailed React Mech 2: 61-109.
45. Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki L, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T. 2006. Proteosome inhibiton with bortezomib enhances activity of topoisomerase-targeting drugs by NF-kB-independent mechanisms. Anticancer Res 26: 1869-1876.
46. Teicher BA. 2008. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271.
47. Thielmann HW, Popamda O, Edler L. 1991. The effects of inhibitors of topoisomerase II, quinacrine of ultraviolet-induced DNA incision in normal and xeroderma pigmentosum fibroblasts. J Cancer Res Clin Oncol 117: 1432-1435.
48. Tse-Dinh YC. 2007. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord Drug Targets 7: 3-9.
49. Wiener JJM, Gomez L, Venkatesan H, Santillan A, Allison BD, Schwartz KL, Shinde S, Tang L, Hack MD, Morrow BJ, Motley ST, Goldschmidt RM, Shaw KJ, Jones TK, Grice CA. 2007. Tetrahydroindazole inhibitors of bacterial type II topoisomerases, Part 2: SAR development and potency against multidrug-resistant strains. Bioorg Med Chem Lett 17: 2718-2722.
50. Yakisich JS, Siden A, Eneroth P, Cruz M. 2001. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem Biophys Res Commun 289: 586-590.